Analystreport

CELLECT BIOTECH/S (NASDAQ: APOP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.

Cellect Biotechnology Ltd. - American Depositary Shares  (APOP) 
US:NASDAQ Investor Relations: cellect.co